San Diego, 09.07.2019

Trovagene Announces Initiation of Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer at Leading Comprehensive Cancer Centers

Trial will evaluate safety and efficacy of onvansertib plus FOLFIRI and Avastin® (bevacizumab) for treatment of patients with KRAS-mutated metastatic. Colorectal Cancer (mCRC). Highly recognized unmet need for 50% of mCRC patients who harbor the KRAS mutation, given current treatment response rate of only 5%. Trovagene to leverage proprietary Precision Cancer Medicine™ tumor genomic technology to assess early indication of treatment response. Trovagene licensed onvansertib (also known as NMS-1286937 and PCM-075) from Nerviano Medical Sciences.
Read more +
Basel, 18.06.2019

Japan becomes the first country to approve Roche’s personalised medicine Rozlytrek (entrectinib)

First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours. Approval supported by the data mainly from the pivotal Phase II STARTRK-2 study showing that Rozlytrek shrank tumours in more than half of people with NTRK fusion-positive solid tumours, across 10 different tumour types, including those with central nervous system metastases. Rozlytrek is also undergoing review in Japan for the treatment of ROS1 fusion-positive non-small cell lung cancer.
Read more +
BOULDER, Colo., 21.05.2019

Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF(V600E)-mutant Metastatic Colorectal Cancer

- BRAFTOVI combinations showed statistically significant improvement in ORR and OS versus control - - BRAFTOVI + MEKTOVI + cetuximab reduced the risk of death by 48% versus control - - Potential to be the first chemotherapy-free, targeted regimen for metastatic CRC patients - - Array intends to submit these data for marketing approval in 2H19 -
Read more +
Nerviano, 03.04.2019

At AACR meeting Nerviano Medical Sciences presents new evidences on its own FLT3/KIT/CSF1R inhibitor and its activities on the identification and characterization of ATP-mimetic choline kinase inhibitors.

These new activities and evidences come from the Kinase platform in Nerviano Medical Sciences, an integrated system of know-how, technologies and intellectual property developed over the years that allows the research Campus a conspicuous synergy in the efficient development of innovative anticancer drugs.
Read more +
Nerviano, 08.03.2019

NMS Group is the sponsor of the Eighth Edition of China Career Day

Agazzi, Chairman of NMS Group: “In the research field challenges know no boundaries by definition and they must be faced through a wide and global approach. With this perspective, for all Group' companies it is essential to become an attractive organization for young talents from all over the world. This initiative of the Italy-China Foundation certainly goes in the right direction and it represents a concrete action to support employers."
Read more +
South San Francisco, CA, 18.02.2019

FDA Grants Priority Review to Entrectinib

Nerviano Medical Sciences is the Originator of Entrectinib, now licesed to Ignyta (Roche Group). Read more on the development of this investigational, oral medicine.
Read more +